Cargando…
Use of antivascular endothelial growth factor for diabetic macular edema
BACKGROUND: Diabetic macular edema (DME) is one of the manifestations of diabetic retinopathy leading to loss of central vision and visual acuity. It manifests itself with swelling around the central part of the retina, the area responsible for sharp vision. Current treatment includes laser therapy...
Autores principales: | Karim, Rushmia, Tang, Benjamin |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879352/ https://www.ncbi.nlm.nih.gov/pubmed/20535227 |
Ejemplares similares
-
Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema
por: Dou, Ningxin, et al.
Publicado: (2021) -
Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
por: Sato, Shinri, et al.
Publicado: (2017) -
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013) -
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012) -
Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion
por: Modi, Yasha S., et al.
Publicado: (2021)